Objective: Obese patients with schizophrenia being treated with clozapine and non-
psychiatric obese are often assumed to share the same physiological changes in obesity …

Objective: Patients with schizophrenia treated with clozapine often gain weight. This study
evaluated the effects of dietary control and physical activity among obese inpatients with …

Background: The aim of this study was to investigate the influence of classical antipsychotics
and the atypical antipsychotic agent clozapine on glucoseinsulin homeostasis to explain …

Objective We tested the hypothesis that fasting blood glucose and insulin levels are higher
in schizophrenic subjects on clozapine monotherapy compared with healthy controls and …

ObjectiveTo assess the prevalence of prediabetes and metabolic abnormalities among
overweight or obese clozapine-or olanzapine-treated schizophrenia patients, and to identify …

Background: Metabolic syndrome (MetS) is a common problem in schizophrenia patients
and associated with increased mortality due to cardiovascular disease. Second-generation …

Objective People with schizophrenia exhibit a high obesity rate. However, little is known
about the prevalence of obesity and its relationship with clinical symptoms and metabolic …

Context: Atypical antipsychotics (SGA) have the propensity to induce weight gain. Objective:
The aim was to evaluateearly changes in hormones involved in neuroendocrine regulations …

INTRODUCTION: Antipsychotic medication and lifestyle factors are implicated in the high
rates of obesity and metabolic syndrome in schizophrenia. While the two Consensus …

Background Schizophrenia (SC) is considered the most serious of all mental disorders.
Some antipsychotics are associated with weight gain and metabolic abnormalities. Whether …